Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

European ADRs Down Nearly 3% Friday as Travel, Energy, Financial Shares Slump

11/26/2021 | 11:12am EST


© MT Newswires 2021
All news about BIONTECH SE
02:05aElicera Therapeutics AB (publ) Interim Report 1 January - 31 December 2021
AQ
01/24BIONTECH : Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccin..
PU
01/24Chile to purchase 2 million Moderna COVID-19 vaccine doses
RE
01/24Today on Wall Street: It's going to be an eventful week
01/24Pfizer-BioNTech Booster Shot Effective Against Omicron, New Study Finds
MT
01/24BIONTECH : Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccin..
PU
01/24Israeli Study Finds Fourth Vaccine Dose Increases Resistance To COVID-19 In People Over..
MT
01/24Who chief tedros says biontech will announce start of production…
RE
01/21Boosters provide 'added protection' against Omicron -CDC
RE
01/21Small children getting less sick from Omicron; Genetic mutation protects against severe..
RE
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 17 374 M 19 647 M 19 647 M
Net income 2021 9 220 M 10 426 M 10 426 M
Net cash 2021 8 824 M 9 979 M 9 979 M
P/E ratio 2021 3,65x
Yield 2021 -
Capitalization 32 202 M 36 465 M 36 414 M
EV / Sales 2021 1,35x
EV / Sales 2022 0,81x
Nbr of Employees 2 800
Free-Float -
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 133,33 €
Average target price 257,15 €
Spread / Average Target 92,9%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-41.44%36 465
GILEAD SCIENCES, INC.-5.56%86 013
REGENERON PHARMACEUTICALS-1.60%64 979
VERTEX PHARMACEUTICALS4.59%58 397
WUXI APPTEC CO., LTD.-5.63%51 604
BEIGENE, LTD.-8.15%25 568